3月24日，美國食品與藥物管理局（FDA）警告，抗心律失常藥物胺碘酮與丙肝抗病毒治療藥物ledipasvir/sofosbuvir（Harvoni）或sofosbuvir（Sovaldi）同時應(yīng)用時可導(dǎo)致患者癥狀性心動過緩。該警告內(nèi)容將會被加入相應(yīng)藥物的說明書中。FDA也將繼續(xù)調(diào)查這種心臟事件的原因。

    信息原文：

    FDA Warns Against Combination of Hepatitis C Treatment and Antiarrhythmic Drug | ACC News StoryOn March 24, the U.S. Food and Drug Administration （FDA） issued a warning against taking the antiarrhythmic drug amiodarone in combination with hepatitis C drug treatments and another direct acting antiviral.

    In their announcement, the FDA stated that amiodarone “taken together with either the hepatitis C drug Harvoni （ledipasvir/sofosbuvir） or with Sovaldi （sofosbuvir）， taken in combination with another direct acting antiviral for the treatment of hepatitis C infection” can cause symptomatic bradycardia. The warning will be added to the labels of Harvoni and Sovaldi, and the FDA will continue to investigate the cause of the heart-related events.